News

Uses of Florbetapir PET Scans Set to Take Shape


 

Neurologists are beginning to get their feet wet prescribing the recently approved PET beta-amyloid imaging agent florbetapir (Amyvid), which is now under consideration for Medicare coverage. In this video, our reporter Michele Sullivan takes you through the process of an Amyvid PET scan, which can help rule out Alzheimer’s disease as a cause of cognitive decline.

Recommended Reading

Drinking Patterns Linked to Cognitive Impairment in Older Adults
MDedge Internal Medicine
Alzheimer's Drug Misses Primary End Points in Trials
MDedge Internal Medicine
Nocturnal Sleep Boosts Working Memory Training in Parkinson's
MDedge Internal Medicine
Changing How We Prescribe Antipsychotics for Dementia
MDedge Internal Medicine
Social Stigma Punishes All Areas of Alzheimer's Care
MDedge Internal Medicine
Clinical, Social Barriers Cripple Adequate Alzheimer's Care
MDedge Internal Medicine
Doctors May Commonly Misdiagnose Creutzfeldt-Jakob Disease
MDedge Internal Medicine
Alzheimer's Imaging Agent Considered for Medicare Coverage
MDedge Internal Medicine
Drugs Set for Testing in Alzheimer's Prevention Trial
MDedge Internal Medicine
Ahead of the Journals: Discontinuing Risperidone in AD
MDedge Internal Medicine